VKTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viking Therapeutics Inc (VKTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows potential for growth due to its promising Phase 3 trials for obesity treatment, positive analyst sentiment, and a strong probability of price appreciation in the next month. While the financials are currently negative, the company's focus on innovative therapeutics and upcoming earnings report could act as a catalyst for future growth.
The stock's moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating an upward trend. However, the MACD is negative and expanding downward, suggesting short-term bearish momentum. RSI is neutral at 31.373, and the stock is trading near its key support level of 32.9, which could act as a potential entry point.
Phase 3 trials for VK2735 to treat obesity show promising preliminary data.
Analyst Michael Ulz maintains an Overweight rating with a high price target of $
Upcoming Q1 2026 earnings report on April 29, 2026, could provide additional insights and drive investor interest.
Financials are currently negative, with no revenue and a net loss of $157.66M in Q4
MACD indicates short-term bearish momentum, which may deter short-term traders.
In Q4 2025, the company reported no revenue growth and a net loss of $157.66M, though net income improved significantly YoY by 345.16%. EPS also improved by 331.25% YoY to -1.38, reflecting better cost management despite no revenue generation.
Morgan Stanley analyst Michael Ulz lowered the price target slightly from $102 to $99 but maintained an Overweight rating, indicating strong confidence in the stock's long-term potential.
